brazil canada china colombia czech republic denmark finland france germany greece hong kong hungary india indonesia ireland israel italy japan korea malaysia singapore mexico netherlands new zealand norway pakistan philippines poland portugal romania russia slovakia south africa spain sweden switzerland taiwan thailand turkey united kingdom ukraine audience navigation health professionalscareerspartnerspartnership highlightscontactsbusiness developments leadersevents pfizer is attendingsubmit your opportunitiesareas of interestbiopharmaceuticalsconsumer healthcarecore therapeutic areasinnovationresearch & developmentclinical innovationgene therapyventure investmentscontact usfrequently asked questionsprivacy policy about us about us discover who we are and what we stand for . meet pfizer . leadership & structuremeet our executives meet our board company fact sheet executive speeches corporate compliancecode of conduct sales & marketing compliance historytimeline gallery of leaders accolades how does pfizer price medicines policy positions value of medicines corporate governanceprinciples fact sheet board committees & charters board policies business conduct and ethics corporate governance faqs contact our directors diversityvision business purpose culture & community supplier diversity products products learn more about our products viewing information intended for residents of the united states . view our product list . authorized distributorspfizer authorized distributors greenstone authorized distributors resource center medical information material safety data sheets counterfeiting research research r & d is at the heart of fulfilling pfizer s purpose as we work to translate advanced science and technologies into the therapies that matter most . see where we re going . therapeutic areas immunology & inflammation cv & metabolic diseases oncology vaccines neuroscience & pain rare disease clinical trialswhat are clinical trials how we conduct trials clinical innovation trial data & results find a trial post marketing commitments r & d partneringworking in r & d r & d ecosystem centers for therapeutic innovation investigator initiated research compound transfer program careers post doc program partnering compassionate use and expanded access science & technologyr & d vision meet our scientists product pipeline operating model r & d platforms biosimilars r & d locations responsibility responsibility as a member of today s rapidly changing global community we are striving to adapt to the evolving needs of society and contribute to the overall health and wellness of our world . see what we re doing . individual voices building healthcare capacityglobal health grants and investments global health fellows expanding access to medicinesinternational trachoma initiative diflucan partnership program pfizer rx pathways relief & emergency humanitarian assistance corporate citizenship global institutions and partnerships reporting trends and progress protecting the environmentsupplier ehs ehs governance key performance indicators pfizer s green journey product stewardship workplace responsibilityhiv aids workplace policy health and safety human rights statement transparencyworking with health care professionals grants and contributionstransparency in grants lobbying & political contributions independent grants for learning & change medical & academic partnerships health care charitables special events device challenge health health at pfizer we believe it is very important for people to take a proactive approach to managing their health . take control of your health . medicine safetymedicine safety education medicine safety at pfizer reporting adverse events patient assistance programsgovernment programs vaccineslegacy of achievement in the developing world meet our vaccines leaders senior healthmedicare resources taking your medications correctly vitamins & your health gethealthy stayhealthy.com biosimilarsbiologics & biosimilars pfizer heritage anatomy of a market leader caregiving health literacypatients and families healthcare professionals public policy researchers rare diseaserare disease home advocacy areas of focus pipeline and clinical trials research grants and contributions business partnering opportunities our rare disease leaders investors investors become an informed investor learn more about investing in pfizer . see what tools we have to offer . shareholder servicesstock faqs advisory information investor dashboard cost basis calculator hospira transaction sec filingsinteractive data filings xbrl presentations financial reports ceo cfo certifications prospective investors hospira exchange offer tax information news news find information and resources for journalists including releases statements and press kits . get the latest . press releasespress release archive press statements press kits & downloadscompany press kit vaccines press kit get old press kit 2016 esmo congress breast cancer a story half told crizotinib resources palbociclib resources ra narrative ttr amyloidosis press kit features frequently requested info social media video gallery contact media relations featured stories senior vs. senior a pfizer summer intern at 70 featured stories applying science to discover therapies that significantly improve and extend people s lives . learn more about us meet the scientist and former smoker supporting patients with metastatic breast cancer ... tackling antibiotic resistance a curious mind dr. gruber in the spotlight find a product a z list of products over the counter products prescription products patient assistance programs pfizer on facebook twitter youtube slideshare linkedin social media for investors pfizer quarterly corporate performance third quarter 2016 press release issued tuesday september 20 2016 audio webcast tuesday november 1 2016 10 00 am e.d.t. morgan stanley global healthcare conference audio webcast tuesday september 13 2016 3 30 pm e.d.t. transcript pdf ... stock quote at . change . vol . day high . 52 wk . high . day low . 52 wk . low . open . mkt . cap bil . prev close . stock symbol . stock exchange . more information for investors press releases pfizer to present new data on xeljanz tofacitinib citrate for ... first positive phase 3 results in adjuvant setting for renal ... pfizer presents promising new immunotherapy combination data ... view all press releases rsstwitter career seekers investors news & media health professionals partners business to business change country contact us sitemap terms of use privacy policy copyright 2002 2016 pfizer inc. all rights reserved . this information including product information is intended only for residents of the united states . the products discussed herein may have different labeling in different countries .